What question did this study set out to answer?

To develop and evaluate a human microglia-based chimeric antigen receptor platform targeting carbonic anhydrase IX (CAIX) and secreting anti-PD-L1 antibodies to treat glioblastoma.

August 1, 2026Journal of NeuroimmunologyOpen Access

CAR microglia-like anti‑carbonic anhydrase IX releasing anti-programmed cell death ligand-1 antibodies for glioblastoma

View Full Paper

Ask AI

Bookmark

Authors

NLNathan Cogliatti Ribeiro de LimaUniversidade Federal do ABC NCNajla Santos Pacheco de CamposUniversidade Federal do ABC RBRenato BarbozaUniversidade Federal de São Paulo

Discussion

Member takes

Implication

Preclinical study demonstrates CAR microglia targeting CAIX reduce tumor burden in glioblastoma models, indicating a strategy to overcome immunosuppression.

Key Points

To develop and evaluate a human microglia-based chimeric antigen receptor platform targeting carbonic anhydrase IX (CAIX) and secreting anti-PD-L1 antibodies to treat glioblastoma.
Engineered human microglial cells to express anti-CAIX CARs with CD28 or 4-1BB costimulatory domains, with or without co-expression of anti-PD-L1 monoclonal antibodies.
Evaluated antigen-specific tumor cell killing and pro-inflammatory cytokine production in vitro.
Assessed antitumor efficacy, tumor burden, and myeloid cell phenotypic reprogramming (measuring CD38, CD86, and HLA-DR) in vivo.
Anti-CAIX CAR-microglia mediated potent antigen-dependent tumor killing in vitro, with CD28-containing constructs driving superior antitumor activity and pro-inflammatory cytokine secretion compared to 4-1BB constructs.
Local delivery of anti-PD-L1 combined with CAIX-targeted CAR microglia significantly reduced in vivo tumor burden compared to control conditions.
Treatment downregulated tumor-derived PD-L1 and reprogrammed tumor-infiltrating myeloid cells into an anti-tumoral M1-like state marked by increased CD38, CD86, and HLA-DR expression.

Cite This Study

Lima et al. (2026) studied this question.

synapsesocial.com/papers/6a78c3e8d2fa2470761f9c83 https://doi.org/10.1016/j.jneuroim.2026.579060

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates CAR microglia targeting CAIX reduce tumor burden in glioblastoma models, indicating a strategy to overcome immunosuppression.

CAR microglia-like anti‑carbonic anhydrase IX releasing anti-programmed cell death ligand-1 antibodies for glioblastoma

Discussion

Member takes

Implication

Key Points

Cite This Study

CAR microglia-like anti‑carbonic anhydrase IX releasing anti-programmed cell death ligand-1 antibodies for glioblastoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider